[1] Charlton MR,Burns JM,Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology,2011,141(4):1249-1253. [2] Perumpail BJ, Khan MA, Yoo ER, et al. Clinicalepidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol, 2017, 23(47):8263-8276. [3] Han J, Wang Y, Yuan Z, et al. Nonalcoholic fatty liver disease represents a greater metabolic burden in patients with atherosclerosis: A cross-sectional study. Medicine (Baltimore),2019,98(11):e14896. [4] Sahebkar A. Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease. World J Gastroenterol,2011,17(2):271-272. [5] Kelly GS. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. Altern Med Rev, 2010, 15(4):313-28. [6] Wang Y. Molecular links between caloric restriction and Sir2/SIRT1 activation. Diabetes Metab J, 2014, 38(5):321-329. [7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.非酒精性脂肪性肝病防治指南 (2018年版).实用肝脏病杂志,2018,21(2):177-186. [8] Finer N. Low-calorie diets and sustained weight loss. Obes Res, 2001, 9(Suppl 4):S290–S294. [9] El-Sayed MI. Effects of Portulaca oleracea L. seeds in treatment of type-2 diabetes mellitus patients as adjunctive and alternative therapy. J Ethnopharmacol, 2011, 137(1):643-651. [10] Oh S, Shida T, Yamagishi K, et al. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study. Hepatology, 2015, 61:1205–1215. [11] Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut, 2011, 60:1278–1283. [12] Lam YY, Peterson CM, Ravussin E. Resveratrol vs. calorie restriction:data from rodents to humans. Exp Gerontol, 2013, 48:1018–1024. [13] Dali-Youcef N, Lagouge M, Froelich S, et al. Sirtuins: the ‘magnificent seven’, function, metabolism and longevity. Ann Med, 2007, 39:335–345. [14] Kelly G. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1. AlternMed Rev, 2010, 15:245–263. [15] Colak Y, Ozturk O, Senates E, et al. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit Basic Res, 2011, 17:HY5–HY9. [16] Nogueiras R, Habegger KM, Chaudhary N, et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev, 2012, 92:1479–1514. [17] Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science, 2004, 305:390–392. [18] Civitarese AE, Carling S, Heilbronn LK, et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med, 2007, 4: e76. [19] Mariani S, Fiore D, Basciani S, et al. Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients. Endocrine, 2014,45:1–6. [20] Akuta N, Kawamura Y, Arase Y, et al. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. BMC Gastroenterol, 2018,18(1):165. |